Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25333171 | 0.87 | MAP4K4 (0.49) | OGAROCK2 | |
| SCHEMBL25332071 | 0.81 | UCHL3 (0.52) | OGAKMT2AMEN1HRH3KDM4E | |
| SCHEMBL15301275 | 0.81 | PRKAB2 (0.48) | OGAROCK2PDE10A | |
| SCHEMBL15300693 | 0.81 | PRKAB2 (0.48) | OGAROCK2PDE10A | |
| SCHEMBL15300847 | 0.81 | PRKAB2 (0.48) | OGAROCK2 | |
| SCHEMBL15300853 | 0.81 | PRKAB2 (0.48) | OGAROCK2 | |
| SCHEMBL15300930 | 0.80 | OGA (0.54) | OGAROCK2MAPTKMT2ALMNA | |
| SCHEMBL2875379 | 0.80 | HTR3E (0.50) | OGAHRH3KDM4E | |
| SCHEMBL25331930 | 0.78 | OGA (0.49) | OGAROCK2NPC1RAB9APDE10A | |
| SCHEMBL30469073 | 0.78 | OGA (0.49) | OGAROCK2NPC1RAB9APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109119-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | EVVIA THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| EP-4469436-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | Evvia Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023147312-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | EVVIA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147312-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | EVVIA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109119-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | PRKAG3, PRKAG1, PRKAG2 | OGA 794/4885ROCK2 940/4885MAPT 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.